E

Epizyme Inc
F:EPE

Watchlist Manager
Epizyme Inc
F:EPE
Watchlist
Price: 559 EUR 3.33%
Market Cap: 92.2B EUR

Relative Value

There is not enough data to reliably calculate the relative value of EPE.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

EPE Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
1 930.7
Median 5Y
1 893.9
Industry
8.2
Forward
1 450
vs History
vs Industry
Median 3Y
-492.7
Median 5Y
-483.3
Industry
24.2
Forward
-361.6
vs History
vs Industry
Median 3Y
-490.6
Median 5Y
-481.3
Industry
23
vs History
vs Industry
Median 3Y
-443.8
Median 5Y
-435.3
Industry
25.5
vs History
vs Industry
Median 3Y
-5 046.3
Median 5Y
-4 950
Industry
3.3
vs History
vs Industry
Median 3Y
1 932.4
Median 5Y
1 895.5
Industry
8.6
Forward
1 451.2
vs History
vs Industry
Median 3Y
2 557.6
Median 5Y
2 508.8
Industry
10.5
vs History
vs Industry
Median 3Y
-536.5
Median 5Y
-526.3
Industry
6.1
vs History
vs Industry
Median 3Y
-522.2
Median 5Y
-512.2
Industry
6.6
vs History
vs Industry
Median 3Y
-491
Median 5Y
-481.7
Industry
8.8
vs History
vs Industry
Median 3Y
-490.4
Median 5Y
-481
Industry
6.8
vs History
vs Industry
Median 3Y
892.7
Median 5Y
875.7
Industry
5.7

Multiples Across Competitors

EPE Competitors Multiples
Epizyme Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Epizyme Inc
F:EPE
94.1B EUR 2 067.2 -527.5 -574.4 -559.1
IL
Can Fite Biopharma Ltd
TASE:CANF
169.9T ILS 61 715 893.4 -4 238 250.4 -4 159 021.2 -4 149 763.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 079 720.5 -161 975.9 -196 690.4 -194 445.9
US
Abbvie Inc
NYSE:ABBV
390.1B USD 6.5 166.2 16.1 22.9
US
Amgen Inc
NASDAQ:AMGN
174.5B USD 4.9 24.9 18 18
US
Gilead Sciences Inc
NASDAQ:GILD
151.2B USD 5.2 18.6 12.5 12.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.5B USD 9.9 31.4 23.1 24.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.9B USD 5.6 17.5 16.6 18.9
AU
CSL Ltd
ASX:CSL
84B AUD 3.6 18.7 12.6 15.7
NL
argenx SE
XBRU:ARGX
42.7B EUR 13.8 32.4 55.8 57.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
48.8B USD 15.2 1 119.2 150.8 182.9
P/S Multiple
Revenue Growth P/S to Growth
US
E
Epizyme Inc
F:EPE
Average P/S: 8 708 886
2 067.2
N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
61 715 893.4
140%
440 827.8
FR
Pharnext SCA
OTC:PNEXF
34 079 720.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.5
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.9
10%
1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
6%
0.9
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
NL
argenx SE
XBRU:ARGX
13.8
49%
0.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
15.2
46%
0.3
P/E Multiple
Earnings Growth PEG
US
E
Epizyme Inc
F:EPE
Average P/E: 178.6
Negative Multiple: -527.5
N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -4 238 250.4 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 975.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
166.2
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.9
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.6
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.4
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.5
10%
1.7
AU
CSL Ltd
ASX:CSL
18.7
11%
1.7
NL
argenx SE
XBRU:ARGX
32.4
40%
0.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 119.2
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
E
Epizyme Inc
F:EPE
Average EV/EBITDA: 38.2
Negative Multiple: -574.4
N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -4 159 021.2 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 690.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.1
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.1
16%
1.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.6
11%
1.5
AU
CSL Ltd
ASX:CSL
12.6
8%
1.6
NL
argenx SE
XBRU:ARGX
55.8
810%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
150.8
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
E
Epizyme Inc
F:EPE
Average EV/EBIT: 44
Negative Multiple: -559.1
N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -4 149 763.3 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 445.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.9
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.1
16%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.9
13%
1.5
AU
CSL Ltd
ASX:CSL
15.7
11%
1.4
NL
argenx SE
XBRU:ARGX
57.3
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
182.9
N/A N/A